Conditional License Agreement for mRNA-based ERA Platform… Total $239M
- Hanall Biopharma obtains an exclusive license from Daewoong Pharmaceutical for the know-how and patents of the mRNA-based Epigenetic Reprogramming of Aging (ERA) platform, securing rights to research, develop, manufacture, and commercialize in ophthalmic and otic areas
- Total deal size is $239 million, consisting of a $1 million upfront payment and $238 million in development milestones; royalties are separate
- This is a conditional agreement; the effective date is when agreed conditions between Hanall and Daewoong are met, and the agreement may be terminated if conditions are not fulfilled
- The technology is currently in preclinical research stage
- The original counterparty changed from Turn Biotechnologies to Daewoong Pharmaceutical (Daewoong acquired Turn's ERA-related assets in May 2026)
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: [Correction of Description] Report on Major Management Matters Related to Investment Decision
- Company: Hanall Biopharma (009420)
- Submission: Hanall Biopharma Co., Ltd.
- Receipt: 05-20-2026
- Under KRX KOSPI Market Division